<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<title>Apotex Inc. v. Ontario (Minister of Health) (October 29, 2004)</title>
<style><!--
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:553679495 -2147483648 8 0 66047 0;}
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;
	font-weight:normal;}
h2
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";}
h3
	{mso-style-next:Normal;
	text-align:right;
	text-indent:-1.0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	tab-stops:-1.0in -.5in .05pt 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in 7.0in 7.5in 8.0in 8.5in 9.0in 9.5in 10.0in 10.5in 11.0in 11.5in 12.0in 12.5in 13.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-bidi-font-weight:normal;}
h5
	{mso-style-next:Normal;
	text-align:center;
	text-indent:-1.0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	tab-stops:-1.0in -.5in .05pt 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in 7.0in 7.5in 8.0in 8.5in 9.0in 9.5in 10.0in 10.5in 11.0in 11.5in 12.0in 12.5in 13.0in;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-bidi-font-weight:normal;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-pagination:widow-orphan;
	background:navy;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.headingtitle, li.headingtitle, div.headingtitle
	{mso-style-name:"heading\: title";
	mso-style-update:auto;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{mso-style-name:"heading\: NUMBER";
	mso-style-update:auto;
	text-align:justify;
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-list:l7 level1 lfo23;
	tab-stops:list .25in left .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingsubtitle, li.headingsubtitle, div.headingsubtitle
	{mso-style-name:"heading\: subtitle";
	mso-style-update:auto;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:4;
	mso-list:l5 level4 lfo21;
	tab-stops:0in .5in list 1.25in left 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingsubsubtitle, li.headingsubsubtitle, div.headingsubsubtitle
	{mso-style-name:"heading\: subsubtitle";
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	mso-list:l5 level5 lfo21;
	tab-stops:0in .5in 1.0in list 1.25in left 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingQUOTE, li.headingQUOTE, div.headingQUOTE
	{mso-style-name:"heading\: QUOTE";
	mso-pagination:widow-orphan;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingblank, li.headingblank, div.headingblank
	{mso-style-name:"heading\: blank";
	mso-style-update:auto;
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l5 level7 lfo21;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.heading3subtitle, li.heading3subtitle, div.heading3subtitle
	{mso-style-name:"heading\: 3subtitle";
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	mso-list:l5 level6 lfo21;
	tab-stops:list 1.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
@page Section1
	{size:8.5in 11.0in;
	mso-header-
	mso-footer-
	mso-title-page:yes;
	mso-header: url() h1;
	mso-paper-source:2;}
div.Section1
	{page:Section1;}
@list l0
	{mso-list-id:-131;
	mso-list-type:simple;
	mso-list-template-ids:1265521074;}
@list l0:level1
	{mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l1
	{mso-list-id:-2;
	mso-list-type:simple;
	mso-list-template-ids:1690878388;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-text:*;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2
	{mso-list-id:248387907;
	mso-list-template-ids:-853636652;}
@list l2:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l2:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l2:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l3
	{mso-list-id:386075433;
	mso-list-type:simple;
	mso-list-template-ids:-1849144142;}
@list l3:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l4
	{mso-list-id:388502664;
	mso-list-type:simple;
	mso-list-template-ids:-1467875128;}
@list l4:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-3.5in;
	font-family:Symbol;}
@list l5
	{mso-list-id:527061025;
	mso-list-template-ids:78953320;}
@list l5:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level4
	{mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subtitle";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subsubtitle";
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: 3subtitle";
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level7
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: blank";
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l5:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6
	{mso-list-id:764231896;
	mso-list-template-ids:1352008676;}
@list l6:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"%3\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l6:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l6:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l7
	{mso-list-id:798916144;
	mso-list-type:simple;
	mso-list-template-ids:-1854087410;}
@list l7:level1
	{mso-level-style-link:"heading\: NUMBER";
	mso-level-text:"\[%1\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-decoration:none;
	text-underline:none;}
@list l8
	{mso-list-id:901141799;
	mso-list-type:simple;
	mso-list-template-ids:-179955282;}
@list l8:level1
	{mso-level-text:"\(%1\)";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l9
	{mso-list-id:911693226;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l9:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l10
	{mso-list-id:996807717;
	mso-list-type:hybrid;
	mso-list-template-ids:665996318 -971106210 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l10:level1
	{mso-level-text:"\(%1\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l11
	{mso-list-id:1250120100;
	mso-list-template-ids:-2020592624;
	mso-list-name:QUOTE;}
@list l11:level1
	{mso-level-number-format:none;
	mso-level-text:"";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l11:level2
	{mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l11:level3
	{mso-level-number-format:none;
	mso-level-text:%3;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l11:level4
	{mso-level-suffix:none;
	mso-level-text:"\(%4\)\0009";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l11:level5
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%5\)\0009";
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l11:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l11:level7
	{mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l11:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l11:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l12
	{mso-list-id:1315601249;
	mso-list-type:simple;
	mso-list-template-ids:-52672024;}
@list l12:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l13
	{mso-list-id:1383941449;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l13:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l14
	{mso-list-id:1550385919;
	mso-list-template-ids:821708086;}
@list l14:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15
	{mso-list-id:1665664019;
	mso-list-template-ids:-1754337048;}
@list l15:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16
	{mso-list-id:1682200304;
	mso-list-template-ids:426402662;}
@list l16:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l16:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l16:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l17
	{mso-list-id:1782457026;
	mso-list-type:simple;
	mso-list-template-ids:1131831968;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18
	{mso-list-id:1816682448;
	mso-list-template-ids:-784801062;}
@list l18:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l18:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"%3\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l18:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l18:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19
	{mso-list-id:2059817004;
	mso-list-template-ids:-1213419456;}
@list l19:level1
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: subtitle";
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l1:level1 lfo27
	{mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:0in;
	text-indent:0in;
	font-family:Symbol;}
ol
	{ul
	{-->
</style>
</head>
<body lang=EN-CA style='tab-interval:.5in' bgcolor="#FFFFFF">
<div class=Section1> 
  <h3>DATE: 20041028<br>
    <b
style='mso-bidi-font-weight:normal'>DOCKET: C39513</b></h3>
  <h5><span style='font-size:15.0pt;mso-bidi-font-size:10.0pt'>COURT OF APPEAL 
    FOR ONTARIO</span></h5>
  <p class=MsoNormal align=center style='text-align:center'><b>BORINS and FELDMAN 
    JJ.A. and THEN J. (<i>ad hoc</i>)</b></p>
  <table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0in 5.4pt 0in 5.4pt' align="center">
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>BETWEEN:</b></p>
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=Style1><b style='mso-bidi-font-weight:normal'>APOTEX INC. <br>
          </b><b style='mso-bidi-font-weight:
  normal'>(Appellant)</b><b style='mso-bidi-font-weight:normal'> </b></p>
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Harry B. Radomski</b><b style='mso-bidi-font-weight:normal'><span
  style='mso-tab-count:1'>  </span>and Julie Perrin<br>
          for the appellant</b></p>
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>- and -</b></p>
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
  style='mso-tab-count:1'>            </span></b></p>
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>MINISTER OF 
          HEALTH, LIEUTENANT GOVERNOR IN COUNCIL and THE ATTORNEY GENERAL OF ONTARIO<br>
          </b><b style='mso-bidi-font-weight:
  normal'>(Respondents)</b><b style='mso-bidi-font-weight:normal'> </b></p>
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Dennis W. Brown, 
          Q.C.<span
  style='mso-tab-count:1'> </span>and James Kendik<br>
          for the respondents</b></p>
      </td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp; 
      </td>
    </tr>
    <tr> 
      <td colspan="2" valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=right style='text-align:left'><b style='mso-bidi-font-weight:normal'>Heard: 
          February 24, 2004</b></p>
      </td>
    </tr>
  </table>
  <p class=MsoHeader><b style='mso-bidi-font-weight:normal'>On appeal from a judgment 
    of Coo, McNeely and Polowin JJ. of the Superior Court of Justice (Divisional 
    Court) dated November 14, 2002.</b></p>
  <p class=MsoHeader><b style='mso-bidi-font-weight:normal'>FELDMAN J.A.:</b></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [1]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>In 1993, the Ontario government instituted 
    a program to limit and control the cost to the government of generic drugs, 
    by imposing a price freeze on all generic drugs and by regulating the price 
    of generic drugs as a percentage of the price of the equivalent brand name 
    drug. This program was known as the 75/90 pricing policy. In 1995, the Divisional 
    Court held that the language of the first legislative attempt to implement 
    the 75/90 policy did not allow the government to set the price of one drug 
    by looking at the price of another drug: <i>Apotex Inc. v. Ontario (Minister 
    of Health) et al.</i> (1995), 77 O.A.C. 360 (Div. Ct.) (“<i>Apotex 1995</i>”). 
    Following that decision, the government amended the relevant legislation and 
    continued the percentage pricing policy and the price freeze. In 1998, the 
    government modified the price freeze on generic drugs by allowing the price 
    of one generic drug product to increase if the price of another was decreased 
    to offset the increase.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [2]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>The issue in this case is whether the two 
    controlling acts, the <i style='mso-bidi-font-style:normal'>Drug Interchangeability 
    and Dispensing Fee Act</i><span style='mso-bidi-font-style:
italic'>, R.S.O. 1990, c. P.23, as am. by S.O. 1996, c.1, Sched. G, ss.&nbsp;19-26 
    (“</span><i style='mso-bidi-font-style:normal'>DIDFA</i><span style='mso-bidi-font-style:
italic'>”)</span><i style='mso-bidi-font-style:normal'> </i>and the <i
style='mso-bidi-font-style:normal'>Ontario Drug Benefit Act</i>, R.S.O. 1990, 
    c.&nbsp;O.10, as am. by S.O. 1996, c. 1, Sched. G, ss. 1-18; S.O. 1997, c. 
    25, Sched. E, s. 9 (“<i>ODBA</i>”), as they were worded in 2000,<a
style='mso-footnote-id:ftn1' href="#_ftn1" name="_ftnref1" title=""><span
class=MsoFootnoteReference><span style='mso-special-character:footnote'> [1] </span></span></a> 
    together with their regulations, gave the government the legislative authority 
    to implement the two aspects of its drug pricing policy. The Divisional Court 
    ([2002] O.J. No.&nbsp;4397) held that they did. For the reasons that follow, 
    I would dismiss the appeal.</p>
  <h2 style='text-align:justify'>FACTS</h2>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [3]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>Through the two Acts, the <i>DIDFA</i> and 
    the <i>ODBA</i>, the Ontario Ministry of Health has established a system called 
    the Formulary, for the recognition of the interchangeability of original or 
    brand name drugs with their generic equivalents and for the listing of drugs 
    covered by its Drug Benefits Program. The purpose of the system is to allow 
    pharmacists to be able to supply a prescribed drug in the cheapest form possible, 
    both to persons who pay for the drugs themselves and to those who qualify 
    to have the government pay for their drugs, referred to as eligible persons. 
  </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [4]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>The <i>DIDFA</i> provides for the designation 
    of interchangeable drug products, that is, generic and brand name products, 
    and the conditions that allow pharmacists to dispense interchangeable drug 
    products, including informing customers of the process of supplying the cheapest 
    interchangeable product unless a prescription indicates that there is to be 
    no substitution, and the maximum dispensing fee. The <i>ODBA</i> governs the 
    supply of drug products at no charge to certain eligible persons who are entitled 
    by law to receive government-supplied drug benefits. The Act sets the parameters 
    for how drugs will be listed in the Formulary, including price requirements, 
    and provides that regulations will set the conditions for the listing of a 
    designated drug product in the Formulary, prescribe the drug benefit price 
    and allowed mark-up for each drug product, as well as the dispensing fee to 
    be charged by the pharmacist. </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [5]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>Each Act plays a distinct role within the 
    scheme, the ultimate goal of which is to make generic drugs available to eligible 
    persons and the rest of the public at low prices. The <i>DIDFA</i> dictates 
    how drug products in the Formulary are deemed to be interchangeable with one 
    another, while the <i>OBDA</i> dictates how drug products are listed in the 
    Formulary as products that may be supplied to eligible persons. Both Acts 
    include conditions with respect to the pricing of generic drugs.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [6]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>In 1993, the Ontario government attempted 
    by regulation to implement a process for controlling the prices of generic 
    drugs as a condition of listing them in the Formulary. That process was called 
    the 75/90 rule. The way it worked was that the brand name original drug could 
    be listed for whatever price the manufacturer chose;<a style='mso-footnote-id:
ftn2' href="#_ftn2" name="_ftnref2" title=""><span class=MsoFootnoteReference><span
style='mso-special-character:footnote'> [2] </span></span></a> then the maximum 
    price for the first interchangeable generic drug could only be 75 per cent 
    of the price of the brand name drug, and the maximum price for the second 
    listed generic drugs, 90 per cent of the first generic drug.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [7]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>In the <i>Apotex 1995</i> case, Apotex challenged 
    the <i style='mso-bidi-font-style:normal'>vires </i>of the 75/90 policy on 
    the ground that the legislation, as it then read, only authorized the Minister 
    to make regulations that set the “best available price” for any particular 
    drug using a method prescribed in the legislation. The Divisional Court agreed 
    with Apotex that the legislation did not allow the Minister to use the price 
    of other drugs as a factor in determining the “best available price” and therefore 
    the regulation was <i style='mso-bidi-font-style:normal'>ultra vires</i>. 
    Following the Divisional Court decision, the legislation was amended in 1996 
    by removing the reference to “best available price,” substituting the “drug 
    benefit price,” and in the <i>ODBA</i>, allowing the Minister to consider 
    the drug benefit price of other drug products in determining the drug benefit 
    price of a particular drug product.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [8]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>The Minister has continued the 75/90 policy, 
    although the percentages have changed, first to 60/90 and then to 70/90, and 
    has implemented a price freeze on all drug products. The generic drug manufacturers 
    and the Ministry held meetings in 1998 and 1999 to develop rules for allowing 
    exceptions to the pricing policy, but the two sides did not reach an agreement. 
  </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [9]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span> <span
style='mso-tab-count:1'>      </span>In addition, a price freeze policy was implemented 
    on all drugs listed on the Formulary as of January 1, 1994. Since 1998, the 
    Ministry has introduced some flexibility to the price freeze policy by stating 
    that it will consider allowing a generic manufacturer to increase the drug 
    benefit price of a particular drug, as long as that manufacturer decreases 
    the drug benefit price of one of its other drugs, with the intent that the 
    net effect to the government when supplying drugs to eligible persons will 
    be cost neutral to the Ontario Drug Benefit Program. </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [10]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant again challenges the <i style='mso-bidi-font-style:
normal'>vires </i>of the regulations implementing these policies and says that 
    the amended legislation does not authorize the Ministry to either freeze prices 
    or to use the price of interchangeable drug products or of drugs products 
    that are not interchangeable to set the price of a particular drug product. 
    The litigation arose as a result of an application by the appellant to raise 
    the price of two of its drug products: Apo-Pherphenazine and Apo-Lisinopril. 
    The appellant’s position was that because its costs of production for the 
    drugs had increased, the existing drug benefit price forced the appellant 
    to sell the two drugs at a loss. The Ministry refused to consider the application 
    until the appellant provided specifics of a countervailing price reduction 
    to offset the proposed increase. The appellant refused to provide that information 
    as part of its application and brought these proceedings to challenge the 
    government’s ability under the <i>DIDFA</i> and the <i>ODBA</i> to enact the 
    price control regulations and policy.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [11]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant also challenges the regulations and the government policy 
    as unlawful on the basis that they are arbitrary, discriminatory, irrational 
    and directed to a purpose that is extraneous to the legislation. The appellant 
    provided the evidence of two experts who both stated that the government’s 
    policies for fixing the prices of drugs do not have the intended effect of 
    reducing the prices, but have the opposite effect of maintaining the prices 
    of many drugs at artificially high levels. The expert evidence is that the 
    most effective method of achieving low prices is by competitive pricing among 
    manufacturers for each drug. The expert evidence is that the 70/90 rule is 
    arbitrary and discriminatory because it allows the brand name drug price to 
    be set by the manufacturer, then dictates a different lower price for subsequent 
    generic drugs based only on the order they become listed in the Formulary. 
    Finally, the experts say the price freeze is not within the objectives of 
    the legislation, which is to achieve the lowest price for drugs, but not a 
    price freeze at an artificial level. This same argument was made in the 1995 
    challenge, but the Divisional Court did not have to deal with it in that case.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [12]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In this case, the Divisional Court dismissed the appellant’s application 
    on both grounds. The Court held that the amended legislation authorizes the 
    Minister to consider the price of other drug products, including the price 
    of drugs that are not interchangeable products, in determining and setting 
    the drug benefit price of a particular drug. The Court also held that there 
    was no evidence on which it was prepared to rely that the processes and policies 
    of the Ministry are arbitrary, discriminatory or irrational, and so long as 
    the government acted within its jurisdiction, it was not the role of the court 
    to assess the correctness of the government’s policies, particularly when 
    they involve the expenditure of public funds.</p>
  <h2>LEGISLATIVE FRAMEWORK RE GOVERNMENT CONTROL OF PRICING</h2>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [13]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> As stated above, the two pieces of legislation and their regulations 
    operate together to implement the entire scheme for the dispensing of interchangeable 
    drug products at lower prices both to eligible persons at the expense of the 
    government and to everyone else. The following summary focuses on the sections 
    that refer to pricing.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-bidi-font-size:12.0pt;mso-ansi-language:EN-US'>[14]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> Section 4 of the <i>DIDFA</i> allows pharmacists who receive 
    a prescription for a specific drug product to dispense a designated interchangeable 
    drug product unless the prescription specifies no substitutions. This section 
    applies to prescriptions for both eligible and non-eligible persons. Section 
    7 applies only to non-eligible persons and provides that for whatever interchangeable 
    drug is dispensed, the pharmacist may only charge the price of the lowest 
    cost interchangeable product plus the dispensing fee, unless the patient has 
    asked for a particular interchangeable product or the prescription directs 
    that there be no substitutions. Section 14 allows the Lieutenant Governor 
    in Council to make regulations (a) prescribing conditions for products and 
    for manufacturers in order to have a product designated as interchangeable 
    and (b) designating products as interchangeable when the Lieutenant Governor 
    in Council considers it advisable to do so “in the public interest.”<span lang=EN-US style='font-size:12.0pt;mso-ansi-language:EN-US'></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-ansi-language:EN-US'>[15]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US style='mso-ansi-language:EN-US'>Regulation 
    935 (amended to 359/01) under the <i>DIDFA</i> defines the Formulary and s. 
    2 states that interchangeable products are designated by their inclusion in 
    Part III of the Formulary. Sections 6, 7 and 8 of that Regulation set out 
    the conditions that must be met for a product to be designated as interchangeable, 
    including the following:</span></p>
  <p class=MsoNormal style='text-align:justify;mso-layout-grid-align:none;text-autospace:none'><span
lang=EN-US style='mso-bidi-font-size:12.0pt;font-family:Symbol;mso-ansi-language:
EN-US'>·<span style='mso-tab-count:1'> </span></span><span lang=EN-US
style='mso-bidi-font-size:12.0pt;mso-ansi-language:EN-US'>Section 6(1)(d) requires 
    the manufacturer to submit as part of its application the “proposed drug benefit 
    price” of the product;</span></p>
  <p class=MsoNormal style='text-align:justify;mso-list:l1 level1 lfo27;mso-layout-grid-align:none;text-autospace:
none'> <span lang=EN-US style='mso-bidi-font-size:12.0pt;
font-family:Symbol;mso-ansi-language:EN-US'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;</span></span><span lang=EN-US style='mso-bidi-font-size:12.0pt;
mso-ansi-language:EN-US'>Section 7(2) requires the drug benefit price of the product 
    to be set in accordance with the 70/90 rule; and</span></p>
  <p class=MsoNormal style='text-align:justify;mso-list:l1 level1 lfo27;mso-layout-grid-align:none;text-autospace:
none'> <span lang=EN-US style='font-family:Symbol;
mso-bidi-font-family:Arial;mso-ansi-language:EN-US'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;</span></span><span lang=EN-US style='mso-bidi-font-size:12.0pt;
mso-ansi-language:EN-US'>Section 8.3 requires that, in order to maintain its designation, 
    the manufacturer be able to continue to supply the product at the drug benefit 
    price and in sufficient quantity to meet the demand for the product.</span><span lang=EN-US style='font-family:Arial;mso-ansi-language:
EN-US'></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [16]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The <i>ODBA</i> regulates the supply of listed drug products to certain 
    eligible persons in Ontario. These are defined to include persons over 65, 
    residents of long-term care and homes for special care facilities, as well 
    as persons who are entitled to receive drug benefits under the <i
style='mso-bidi-font-style:normal'>Family Benefits Act</i>, the <i
style='mso-bidi-font-style:normal'>Ontario Disability Support Program Act</i>, 
    <i
style='mso-bidi-font-style:normal'>1997 </i>and the <i style='mso-bidi-font-style:
normal'>Ontario Works Act, 1997</i> (see s. 2 of the Act and s. 2 of Regulation 
    201/96).</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [17]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Section 6 mandates the amount that the Minister will pay the pharmacist 
    for supplying a listed drug product to an eligible person, including three 
    components prescribed by regulation: (a) the dispensing fee, (b) the drug 
    benefit price for that product or for the lowest-priced interchangeable listed 
    drug product, and (c) the mark-up on the applicable drug benefit price.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [18]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Section 16 makes it a condition of designation of a listed drug product 
    that the manufacturer “supply that drug product for the same price to all 
    purchasers in Ontario, other than public hospitals purchasing solely for use 
    in the treatment of patients and out-patients in the hospital, where the purchasers 
    purchase the same quantity of individual units of the drug product in the 
    same dosage form and strength.”</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [19]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Section 18 gives the Lieutenant Governor in Council the power to make 
    regulations including: (b) prescribing conditions for listed drug products, 
    (c) designating listed drug products in the public interest and so long as 
    the products have met the prescribed conditions, and (g) “subject to section 
    22, prescribing the drug benefit price for listed drug products.” Subsection 
    18(3) specifies that the conditions for listing can include conditions “relating 
    to the drug benefit price of the drug product <i
style='mso-bidi-font-style:normal'>or other drug products</i>…” [emphasis added].<span style="mso-spacerun: yes">  
    </span>When the Lieutenant Governor in Council decides to designate or remove 
    the designation of a listed drug under s. 19, it may consider matters in the 
    public interest including the drug benefit price of the drug product <i style='mso-bidi-font-style:normal'>or 
    other drug products</i>. </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [20]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Finally, ss. 22(1) and (2) provide that the drug benefit price for 
    a listed drug product shall be the price submitted by the manufacturer and 
    agreed to by the Minister, and that “[i]n deciding whether to agree to an 
    amount submitted by the manufacturer, the Minister may consider any matter 
    the Minister considers advisable in the public interest, including, without 
    limiting the generality of the foregoing, <i style='mso-bidi-font-style:normal'>the 
    drug benefit price of other drug products</i>…” [Emphasis added].</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [21]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Regulation 201/96 (amended to 16/01) under the <i>ODBA</i> sets out 
    in s. 11 the conditions for designation of an interchangeable drug product 
    under the <i>DIDFA</i><span style='mso-bidi-font-style:italic'>,</span> as 
    a listed drug product under the <i>ODBA</i><span style='mso-bidi-font-style:
italic'>,</span> including compliance with the 70/90 price rule for interchangeable 
    drug products.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [22]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The effect of the two Acts on the price of drug products listed in 
    the Formulary is two-fold. First, generic drugs can only be designated in 
    the Formulary as interchangeable with other drugs if they have a drug benefit 
    price that complies with the 70/90 price formula. I note that as part of the 
    overall scheme, the <i>DIDFA</i> incorporates the “drug benefit price” concept 
    from the <i>ODBA</i>, even though the <i>DIDFA </i>does not deal with drug 
    benefits.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [23]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Second, drugs that are designated as listed drug products in the Formulary 
    for the purposes of supply to eligible persons by the government are given 
    a drug benefit price that (a) complies with the 70/90 price formula and (b) 
    may be required to be adjusted according to the prices of other drugs. The 
    result is that in order to have their drug products dispensed by pharmacists 
    from the Formulary, both to eligible and non-eligible persons, the drug manufacturers 
    must comply with the price requirements imposed by the Minister under both 
    Acts.</p>
  <h2>ISSUES</h2>
  <p class=headingQUOTE style='text-align:justify;mso-list:l10 level1 lfo26;'> 
    (1)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Are the price freeze policy and the 70/90 regulations <i
style='mso-bidi-font-style:normal'>ultra vires</i> the legislature under the legislation 
    as currently worded? </p>
  <p class=headingQUOTE style='text-align:justify;mso-list:l10 level1 lfo26;'> 
    (2)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> If the policy and regulations are not <i style='mso-bidi-font-style:
normal'>ultra vires</i>, are they nevertheless unlawful as arbitrary, discriminatory 
    and not within the purpose of the legislation?</p>
  <h2>ANALYSIS</h2>
  <p class=MsoNormal style='text-align:justify;'><span
style='mso-tab-count:1'>            </span><b>Issue One:<span style='mso-tab-count:
1'>     </span>Does the Current Wording of the Legislation Allow the Minister 
    to Impose a Price Freeze Policy and the 70/90 Price Formula?</b></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> <span lang=EN-US
style='mso-bidi-font-size:12.0pt;mso-ansi-language:EN-US'>[24]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> The appellant’s basic premise is that the legislative scheme 
    of the two acts is intended to achieve low prices for interchangeable drugs 
    through price competition, and not by the artificial fixing and controlling 
    of drug prices. The appellant submits that there is nothing in the legislation 
    that gives the Minister the authority to impose either the 70/90 pricing policy 
    or the price freeze policy: <i><span lang=EN-US
style='mso-bidi-font-size:12.0pt;mso-ansi-language:EN-US'>Re Doctors Hospital 
    and Minister of Health et al.</span></i><span lang=EN-US style='mso-bidi-font-size:
12.0pt;mso-ansi-language:EN-US'> (1976), 12 O.R. (2d) 164 (Div. Ct.) at 175; <i>Canada 
    v. National Fish Co.</i>, [1931] Ex. C.R. 75 at 82. </span>The appellant refers 
    back to the 1995 decision of the Divisional Court that struck down the 75/90 
    policy on the ground that the legislation, as it was then worded, did not 
    authorize the Minister to set prices by reference to the prices of other drugs. 
    That court stated that if the government wished to allow the price of drugs 
    to be limited in that way, it would have to amend the statutes: <i>Apotex 
    1995, supra</i> at 366. <span lang=EN-US style='mso-bidi-font-size:12.0pt;mso-ansi-language:
EN-US'></span></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [25]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I have described the legislative provisions in both the <i>DIDFA</i> 
    and the <i>ODBA</i> as well as the regulations under each statute that refer 
    to the Minister’s power to set the drug benefit price. In my view, those provisions 
    give the government the authority to set the price of interchangeable drug 
    products, both by reference to the price of other drug products with which 
    the particular drug is interchangeable – the 70/90 rule – and by referencing 
    the price of unrelated drugs in order to effectively impose a price freeze 
    on all drugs supplied to eligible persons.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [26]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant submits that there is no provision in the <i>DIDFA</i> 
    that specifically gives the government the authority to set the prices of 
    drug products, except the power in s. 14(1)(a) to regulate prescribed conditions 
    for designation of products as interchangeable, a provision that existed in 
    the 1995 version of the Act when the Divisional Court decided <i>Apotex 1995</i>. 
    However, the 1995 version of the Act required the government to determine 
    prices by ascertaining the “best available price” of the generic drugs on 
    the market and then to fix the price through regulation. With this mechanism 
    in place, the condition-making power in s. 14(1)(a) was not sufficient to 
    allow the government to relate that price to the price of other drug products: 
    <i>Apotex 1995, supra </i>at 366<i>.</i></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [27]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The current <i>DIDFA</i> and the <i>ODBA</i> have eliminated the “best 
    available price” concept and refer only to the drug benefit price. I see nothing 
    in the <i>DIDFA</i> that prevents the government from regulating a price formula 
    relating the price of interchangeable drugs as one of the conditions for designation 
    of interchangeability (s.&nbsp;7(2) of Reg. 935) and to consider that price 
    formula to be in the public interest (s.&nbsp;14(1)(b) of the Act). Furthermore, 
    because the <i>DIDFA</i> is concerned with supplying the public with the lowest 
    priced interchangeable drug products, the price comparison among interchangeable 
    products is a critical factor in implementing the purpose of the Act. </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [28]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The <i>ODBA</i> contains specific language that authorizes the government 
    to set the drug benefit price of each drug product that is listed in the Formulary 
    and, in so doing, the Minister is allowed to consider “any matter the Minister 
    considers advisable in the public interest” including “the drug benefit price 
    of other drug products” (ss. 18 and 22). This broadly worded language can 
    apply to both the price of other interchangeable drug products, as well as 
    to the price of other drug products that are not linked to the particular 
    product. In other words, this language is broad enough to authorize both the 
    70/90 rule and the price freeze policy that only allows the price of one product 
    to rise if it is offset by a price reduction of another product.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [29]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant argues that the thrust of s. 22 is that the drug benefit 
    price is to be set by agreement between the manufacturer and the Minister, 
    so that the Minister can be made aware of factors such as costs of production 
    that will impact the price to be charged. However, this argument effectively 
    ignores s. 22(2), which grants the Minister the power to consider the factors 
    the Minister considers in the public interest before agreeing to a price suggested 
    by a manufacturer, one such factor being the price of other drug products, 
    a factor that is extraneous to the cost of production and other normal components 
    of price.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [30]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Because there is only one drug benefit price assigned to each drug 
    product listed in the Formulary, the authority given to the minister in the 
    <i>ODBA</i> affects the price of drug products in the Formulary for the purposes 
    of the <i>DIDFA</i> as well. That is the effect of the interrelation of the 
    two acts for the purpose of implementing the policies of each one. </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [31]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> One of the appellant’s objections to the decision of the Divisional 
    Court in this case is that that court appeared to believe that the two Acts 
    only control the prices paid by the government for drug products for eligible 
    persons, and that manufacturers are free to charge any price to everyone else. 
    In his affidavit, filed on behalf of the Ministry, the Associate Director 
    of the Drug Programs Branch of the Ministry of Health and Long Term Care, 
    Frank Felice, states that, “Although manufacturers are able to increase their 
    prices in the market place, the drug benefit price that will be reimbursed 
    for ODB claims is set by regulation.” The Divisional Court may have been referring 
    to this statement when it said at paragraph 7 of its judgment that this case 
    is about the prices paid by government for generic drugs and that the scheme 
    of the Acts “exerts no theoretical control over the price to be charged outside 
    the government reimbursement scheme.”</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [32]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I agree with the appellant that the effect of the scheme of the two 
    Acts is to control the prices paid by everyone in Ontario for drugs that are 
    listed in the Formulary. Counsel for the respondent acknowledged in oral argument 
    that the Divisional Court was in error when it made that comment. However, 
    to the extent that the Divisional Court was in error, that error does not 
    affect the correctness of the result reached by the Divisional Court, based 
    on the interpretation of the legislative authority granted to the Minister 
    in the two Acts and their regulations.</p>
  <p class=MsoNormal style='text-align:justify;'><span
style='mso-tab-count:1'>            </span><b>Issue 2:<span
style="mso-spacerun: yes">  </span>If the price<span style="mso-spacerun:
yes">  </span>freeze policy and the 70/90 regulations are not <i
style='mso-bidi-font-style:normal'>ultra vires</i>, are they nevertheless unlawful 
    as arbitrary, discriminatory and not within the purpose of the legislation?</b></p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [33]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant filed the affidavits of two experts in health economics, 
    Professor Aslam Anis of the University of British Columbia and Professor Iain 
    Cockburn of the University of British Columbia and Boston University. Both 
    experts express the opinion that the 70/90 price regulations are an ineffective 
    way of lowering the cost of drugs in Ontario and that the regulations do not 
    foster lower pharmaceutical expenditures. On the contrary, they say that the 
    policy encourages generic drug manufacturers to seek the greatest allowable 
    initial listing price under the 70/90 rule, even if its costs of production 
    would allow a much lower price to be acceptable if competition were the governing 
    factor in setting the price. Furthermore, a 2001 study by the Provincial Auditor 
    of Ontario concluded that drug prices were lower in provinces where manufacturers 
    set prices through competition and recommended that the Ministry re-evaluate 
    the 70/90 regulations.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [34]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The experts also suggest that there is no basis for choosing the level 
    of 70 per cent and therefore the regulation is arbitrary. They say it is discriminatory 
    because it affects manufacturers of different drugs differently. It discriminates 
    against manufacturers of generic drugs as opposed to brand name drugs, and 
    it discriminates between first and subsequent generic manufacturers of a particular 
    drug.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [35]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Finally, the appellants submitted an affidavit sworn by Jack Kay, 
    president and chief operating officer of Apotex, who argues that the government’s 
    policy is arbitrary because it does not take into account the manufacturer’s 
    ability to sustain an adequate return on its products. For example, he states 
    that Apotex is selling the drug products at issue in this case, Apo-Lisinopril 
    and Apo-Perphenazine, at a loss.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [36]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Ministry filed no expert evidence in response on the economic 
    impact of the 70/90 regulation or the effectiveness of the price freeze policy. 
  </p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [37]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Consequently, the record before the court does raise concerns as to 
    whether the government’s drug pricing policy may have the effect of increasing 
    the cost of generic drugs for the government and the public rather than lowering 
    that cost. However, it is a policy of the government that has been enacted 
    for a purpose, and therefore cannot be said to be arbitrary or irrational. 
    If the policy does not work the way it was intended, as suggested by some 
    of the evidence before the court, that is a matter to be considered by the 
    government. On the other hand, if the government’s price freeze policy has 
    had the effect of keeping its drug costs relatively stable since 1994, that 
    stability is also a factor that the government will weigh when considering 
    the effectiveness of the policy.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [38]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The appellant also suggests that the policy is illegal because it 
    discriminates among drug manufacturers. I reject this suggestion. The purpose 
    and effect of the drug pricing policy is to achieve the lowest prices for 
    drug products and to ensure that the lowest-priced interchangeable products 
    are supplied to eligible persons and are made available to everyone else. 
    The structure of the policy dictates different price levels for drug products 
    depending on a variety of relevant factors, including the timing of an application 
    for interchangeability status in the Formulary and the public interest. This 
    structure cannot be viewed as discriminatory in an arbitrary or illegal sense.</p>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [39]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I agree with the Divisional Court’s conclusion that the responsibility 
    for the management of public funds rests with the government and not the court, 
    as does the correctness of the government’s decisions and policies, especially 
    in the context of a specialized legislative scheme such as this one. Although 
    the drug pricing policy under the <i style='mso-bidi-font-style:
normal'>DIDFA</i> and the <i style='mso-bidi-font-style:normal'>ODBA</i> affects 
    the price of drugs for everyone in Ontario, one of its main purposes is to 
    achieve a low cost to the government for drug products it supplies to eligible 
    persons.</p>
  <h2>CONCLUSION<span style='font-weight:normal'></span></h2>
  <p class=headingNUMBER align=left style='text-align:left;
line-height:normal'> [40]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I would therefore dismiss the appeal, with costs on the partial indemnity 
    scale. The parties advised the court that they would agree on the amount of 
    costs to be fixed. </p>
  <p class=MsoNormal>Signed:<span style='mso-tab-count:
1'>           </span>“K. Feldman J.A.”</p>
  <p class=MsoNormal><span style='mso-tab-count:2'>                        </span>“I 
    agree S. Borins J.A.</p>
  <p class=MsoNormal><span style='mso-tab-count:2'>                        </span>“I 
    agree Edward Then J. (<i>ad hoc</i>)</p>
  <p class=MsoNormal><b>Released: “KNF” October 28, 2004</b></p>
</div>
<div style='mso-element:footnote-list'> <br clear=all>
  <hr align=left size=1 width="33%">
  <div style='mso-element:footnote' id=ftn1> 
    <p class=MsoFootnoteText><a style='mso-footnote-id:ftn1' href="#_ftnref1"
name="_ftn1" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'> [1] </span></span></a><span
style="mso-spacerun: yes">   </span>This case deals with the <i>DIDFA</i> and 
      the <i>ODBA</i> as they appeared in 1999 and 2000, when Apotex sought to 
      raise the prices of two of its drug products, leading to the instant case. 
      Both Acts have subsequently been amended, the <i>DIDFA</i> by S.O. 2004, 
      c. 7, s. 7 and the <i>ODBA</i> by S.O. 2002, c. 18, Sched. I, s. 18; S.O. 
      2004, c. 3, Sched. A, s. 95; S.O. 2004, c. 7, s. 14.</p>
  </div>
  <div style='mso-element:footnote' id=ftn2> 
    <p class=MsoFootnoteText><a style='mso-footnote-id:ftn2' href="#_ftnref2"
name="_ftn2" title=""><span class=MsoFootnoteReference><span style='mso-special-character:
footnote'> [2] </span></span></a><span
style="mso-spacerun: yes">   </span>It should be noted, however, that the pricing 
      of brand name drugs is not wholly unconstrained. The federal Patented Medicine 
      Prices Review Board, a creature of the <i>Patent Act</i>, R.S.C. 1985, c. 
      P-4, monitors and sets guidelines for the pricing of patented drugs. Through 
      this oversight mechanism, the cost of brand name drugs is moderated.</p>
  </div>
</div>
</body>
</html>
